Infliximab therapy improves physical function in patients with psoriatic arthritis - 21/08/11
Arthur Kavanaugh, MD, University of California, San Diego, Division of Rheumatology, Allergy, and Immunology, La Jolla, CA, United States; Songkai Yan, PhD, Anna Beutler, MD, Centocor, Inc., Malvern, PA, United States; Christian Antoni, MD, Friedrich-Alexander University, Erlangen, Germany
Le texte complet de cet article est disponible en PDF. P2824 Dr. Kavanaugh has consulted for and participated in clinical research sponsored by Centocor, Amgen, and Abbott Laboratories. Dr. Antoni is an investigator and consultant for infliximab at Centocor. Studies have been funded by research grants from Centocor (IMPACT) or have been done by Centocor (IMPACT 2). |
Vol 52 - N° 3S
P. P203 - mars 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?